​Pharmacology - Proguanil

​Pharmacology - Proguanil 
An action of the slow blood schizonticide 

Action Process
Prevents the malaria parasite from producing thymidylate by blocking its enzyme, dihydrofolate reductase (DHFR).
Orally administered, the half-life is sixteen hours.

Medical Application
 To prevent malaria, typically in conjunction with chloroquine.
In certain areas, proguanil + atovaquone is utilized for both falciparum malaria therapy and chemoprophylaxis.

Potential Side Effects
Very few because the medicine does not block the host's DHFR. Uncommon: gastrointestinal (GI) issues, redness, oral ulcers, thinning hair.